ARID1A and ovarian carcinoma: The loss of ARID1A has been linked to the activation of MAPK signalling [180], sensitivity to PI3K/AKT/mTOR inhibitors and ATR inhibitors [161,181], as well as aurora kinase inhibition [182], warranting further investigation for the development of molecularly targeted therapies against ARID1A-mutated ovarian cancers.